The Worldwide Drug Discovery Services Industry is Expected to Reach $31.4 Billion by 2026 – ResearchAndMarkets.com – Yahoo Finance

DUBLIN, February 15, 2022–(BUSINESS WIRE)–The "Drug Discovery Services Market by Process (Target Selection, Validation, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small molecules, biologics), Therapeutic Area (Oncology, Neurology) End User (Pharma, Biotech) – Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
The global Drug discovery services market is projected to reach USD 31.4 billion by 2026 from USD 16.1 billion in 2021, at a CAGR of 14.3% during the forecast period of 2021 to 2026.
Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are creating new revenue pockets in the drug discovery services market.
The chemistry services segment accounted for the largest share of the type segment in the drug discovery services market in 2020
Based on type, the drug discovery services market is segmented into chemistry and biology services. The chemistry services segment commanded the largest share of this market in 2020. Growth in this market segment is largely due to the widespread application of chemistry in various early drug development phases to deliver robust candidates. The extensive usage of chemistry in academics, biotechnology companies, and large pharmaceutical companies also supports market growth.
The Hit-to-lead identification segment accounted for the largest share of the process segment in the drug discovery services market in 2020
Based on process, the drug discovery services market is broadly classified into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification segment accounted for the largest share of the drug discovery services market in 2020. Due to its vital role in drug discovery, hit-to-lead identification is the most revenue-generating process, and currently, many CROs are offering these services to pharmaceutical companies.
The Oncology segment accounted for the largest share of the therapeutic area segment in the drug discovery services market in 2020
Based on therapeutic area, the drug discovery services market is segmented into oncology, infectious and immune system diseases, neurology, digestive system diseases, cardiovascular diseases, and other therapeutic areas. Oncology is the largest segment in this market owing to the high incidence of cancer, a growing number of research studies on cancer therapeutics, and a company focus on bringing innovative cancer drugs into the market.
Asia Pacific: The fastest-growing region in the drug discovery services market
The drug discovery services market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). The APAC is estimated to record the highest CAGR during the forecast period. The vast patient population, emerging middle-class, rising government spending, and therapeutic area expertise are the major growth drivers for the pharmaceutical industry in the region. Global pharmaceutical firms are increasingly moving to Asia to tap into its thriving market and lower their production costs by shifting manufacturing to the region.
Market Dynamics
Drivers
Growing R&D Expenditure in the Pharma & Biopharma Industry
Increasing Demand for Outsourcing Analytical Testing
Initiatives for Research on Rare Diseases and Orphan Drugs
High Cost of In-House Drug Development
Restraints
Stringent Regulations Governing Drug Discovery and Animal Usage
Opportunities
Growth in Drugs and Biologics Market Despite COVID-19 Pandemic
Rising Demand for Specialized Testing Services Among End-users
Patent Expiry
High Growth Prospects in Emerging Markets
Challenges
Shortage of Skilled Personnel
Trends
Shift in Drug Discovery Services due to Growing Adoption of Ai-Based Tools
Increased Outsourcing to Emerging Asian Economies
Cro Industry Consolidation
Integrated End-To-End R&D Service Solution
Companies Mentioned
Laboratory Corporation of America Holdings
Charles River Laboratories International, Inc.
Wuxi Apptec
Thermo Fisher Scientific
Pharmaron Beijing Co., Ltd.
Evotec Se
Eurofins Scientific Se
Pharmaceutical Product Development, Inc.
Piramal Enterprises Limited
Syngene International Limited
Curia Global Inc.
Genscript Biotech Corporation
Jubilant Pharmova Limited
Frontage Holdings Corporation
Shanghai Medicilon Inc.
Dr. Reddy's Laboratories Ltd. (Aurigene Discovery Technologies)
Selvita S.A. (Formerly Selvita Cro S.A.)
Viva Biotech (Shanghai) Ltd.
Tcg Lifesciences Pvt Ltd.
Shanghai Chempartner Co., Ltd.
Domainex Ltd.
Nuvisan Pharma Holding GmbH
Dalton Pharma Services
Aragen Life Sciences Pvt. Ltd. (Formerly Gvk Biosciences Pvt. Ltd.)
Promega Corporation
For more information about this report visit https://www.researchandmarkets.com/r/a6t17u
View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005996/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fuel cell company Plug Power's (NASDAQ: PLUG) stock price continued to power higher on Tuesday, still coasting on the updraft that it got from peer Bloom Energy's (NYSE: BE) positive earnings report late last week — and the big vote of confidence Bloom got from Bank of America Monday. In fact, it looks like all of the major fuel cell stocks were rising Tuesday. As of 3 p.m. ET, Plug Power stock was up by 11%, Bloom was up by 13.2%, Ballard Power (NASDAQ: BLDP) had tacked on 10.2%, and FuelCell Energy (NASDAQ: FCEL) — head and shoulders above the rest — was sitting on an 18.4% gain.
Roblox reported its Q4 earnings after the bell on Tuesday, missing Wall Street's expectations.
Wednesday's question-and-answer session could provide insight into the company's path to commercialization.
Net worth is a financial metric that can help you keep your individual picture of your finances in perspective. The average net worth by age, in this case, refers to the net worth of the households in the U.S. divided … Continue reading → The post Average Net Worth by Age appeared first on SmartAsset Blog.
Novavax (NASDAQ: NVAX) was up by 5%, while Dynavax Technologies (NASDAQ: DVAX) had gained 5.2%, and Ocugen (NASDAQ: OCGN) was up by 4.9%. This survey, conducted by The Harris Poll on behalf of Ocugen, found that 73% of Americans "would like to see additional [COVID-19] vaccine options available that are developed from a more traditional method."
The race is on to add dividends to stock portfolios. But investors are still being picky in the S&P 500 — and know what they're looking for.
The stock market is often an exercise in reverse psychology. When a stock goes up, investors instinctively want to get a piece of the action. Likewise, when a stock drifts to the bottom, the natural inclination is to run away. But any investor worth their salt knows they need to battle against those natural impulses as the bottom is often the most appealing starting point; because it is from there that the real gains are made. Of course, not any stock lying in the doldrums is worth picking up, t
The prince's lawyers said they have reached a settlement with Giuffre, who accused Andrew of sexually abusing her.
Before Thursday’s market action kicks off, Palantir (PLTR) will deliver fourth-quarter financials. Deutsche Bank’s Brad Zelnick expects the results will come in according to the guide, which calls for revenue of $418 million. However, the 5-star analyst believes most of the investor focus will turn to the “sustainability and quality of growth and any initial view for C1Q22 and CY22.” Zelnick notes that the slowdown in Government and Commercial revenue, coupled with “contribution margin compressi
Micron Technology Inc., (NASDAQ:MU) seems unusually attractive when compared to a select set of peers. Today, we will explore how we can do competitor analysis on a fundamental level and see why Micron seems to stand out.
Berkshire Hathaway bought Activision Blizzard before Microsoft swooped in. Not all "Warren Buffett stocks" are actually his picks.
Solid performance is expected in the chip maker's gaming and data center businesses when it reports earnings Wednesday.
EV maker Lucid Motors now employs 2,000 people in Arizona, most of whom live and work around its Casa Grande production facilities. The company wants to hire an additional 1,000 people by year's end, but it warns that housing and basic services in the area may soon be strained.
Yahoo Finance's Jared Blikre reports on Airbnb earnings beating estimates.
Semiconductor stocks exploded higher on Tuesday afternoon, riding a rising tide of positive market sentiment as the stock market responded to news of an apparent Russian troop pullback from Ukraine — and the potential that war in Eastern Europe can be averted. As of 3:30 p.m. ET, shares of Qualcomm (NASDAQ: QCOM) had risen 4.8%, Advanced Micro Devices (NASDAQ: AMD) was up 6.1%, and Micron (NASDAQ: MU) had gained most of all — up 7.1%. Positive news out of Moscow appears to be the primary catalyst moving stocks higher today, but it wasn't the only good news for investors in tech stocks in general, or semiconductor stocks in particular.
Mortgage REITs sport incredibly high dividend yields, but how vulnerable are those yields to rising interest rates?
(Bloomberg) — Elon Musk gifted almost $6 billion worth of Tesla Inc. stock to charity late last year in one of the largest philanthropic donations in history.Most Read from BloombergElon Musk Donated $5.7 Billion of Tesla Shares to CharityPutin Seeks Diplomatic Solution Amid ‘Partial’ Troop PullbackPutin Sees Basis for Talks After Scholz Meeting: Ukraine UpdateTrump's Accountants Just Quit. What Took So Long?Sarcasm in Ukraine Roils Markets Swinging Between War, PeaceThe world’s richest man don
Futurum Research Principal Analyst Daniel Newman  joins Yahoo Finance Live to discuss how Intel acquiring Tower Semiconductor will bring in more growth opportunities.
Semiconductor stock Nvidia (NASDAQ: NVDA) got another lift on Tuesday morning when investment bank Piper Sandler predicted — on the day before fourth-quarter earnings arrive — that Nvidia will deliver a "significant beat and raise," as StreetInsider.com reported this morning. "Overall, demand [for Nvidia's chips] continues to be strong for gaming given the adoption of RTX GPUs with ray tracing," Piper Sandler said this morning. In short, Piper Sandler is predicting that Nvidia will exceed expectations for 48% quarterly revenue growth and 58% earnings growth in its fourth-quarter report.
Yahoo Finance's Julie Hyman and Brian Sozzi discuss David Einhorn shorting Tesla again.

source

Add a Comment

Your email address will not be published. Required fields are marked *